A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T-cell engager, in patients with advanced solid tumors.

Authors: Sandra P. D'Angelo, Vivek Subbiah, Jean-Yves Blay, Michael J. Wagner, Neeltje Steeghs, Jeonghwan Youk, Hideki Mizusako, Yoshihiro Ohue, Jin Jin, Abdul Waheed Rajper, Nicole Tesar, Patrick Schöffski

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2668

Source: Full article

---

Abstract

TPS2668